BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18624722)

  • 1. Activation of B-Myb by E2F1 in hepatocellular carcinoma.
    Nakajima T; Yasui K; Zen K; Inagaki Y; Fujii H; Minami M; Tanaka S; Taniwaki M; Itoh Y; Arii S; Inazawa J; Okanoue T
    Hepatol Res; 2008 Sep; 38(9):886-95. PubMed ID: 18624722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
    Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
    J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53.
    Calvisi DF; Simile MM; Ladu S; Frau M; Evert M; Tomasi ML; Demartis MI; Daino L; Seddaiu MA; Brozzetti S; Feo F; Pascale RM
    Hepatology; 2011 Apr; 53(4):1226-36. PubMed ID: 21480327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of over-expressed TFDP1 with progression of hepatocellular carcinomas.
    Yasui K; Okamoto H; Arii S; Inazawa J
    J Hum Genet; 2003; 48(12):609-613. PubMed ID: 14618416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
    Guan Z; Cheng W; Huang D; Wei A
    Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
    Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
    Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
    Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
    Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1.
    Gu Y; Wang X; Liu H; Li G; Yu W; Ma Q
    Oncol Rep; 2018 Oct; 40(4):1863-1874. PubMed ID: 30106440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
    Frau M; Feo F; Pascale RM
    J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.
    Xin Z; Li Y; Meng L; Dong L; Ren J; Men J
    Math Biosci Eng; 2022 Jan; 19(2):1825-1842. PubMed ID: 35135230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.
    Baiz D; Pozzato G; Dapas B; Farra R; Scaggiante B; Grassi M; Uxa L; Giansante C; Zennaro C; Guarnieri G; Grassi G
    Biochimie; 2009 Mar; 91(3):373-82. PubMed ID: 19041685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins.
    Choiniere J; Wu J; Wang L
    Mol Pharmacol; 2017 Mar; 91(3):189-196. PubMed ID: 28003426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-34a induces the downregulation of both E2F1 and B-Myb oncogenes in leukemic cells.
    Zauli G; Voltan R; di Iasio MG; Bosco R; Melloni E; Sana ME; Secchiero P
    Clin Cancer Res; 2011 May; 17(9):2712-24. PubMed ID: 21367750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic B-Myb Is Associated With Deregulation of the DREAM-Mediated Cell Cycle Gene Expression Program in High Grade Serous Ovarian Carcinoma Clinical Tumor Samples.
    Iness AN; Rubinsak L; Meas SJ; Chaoul J; Sayeed S; Pillappa R; Temkin SM; Dozmorov MG; Litovchick L
    Front Oncol; 2021; 11():637193. PubMed ID: 33747961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of E2F1-cyclin E1-E2 circuit down regulation in hepatocellular carcinoma cells.
    Farra R; Dapas B; Pozzato G; Scaggiante B; Agostini F; Zennaro C; Grassi M; Rosso N; Giansante C; Fiotti N; Grassi G
    Dig Liver Dis; 2011 Dec; 43(12):1006-14. PubMed ID: 21831731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYBL2 is a new regulator of flavonoid biosynthesis in Arabidopsis thaliana.
    Dubos C; Le Gourrierec J; Baudry A; Huep G; Lanet E; Debeaujon I; Routaboul JM; Alboresi A; Weisshaar B; Lepiniec L
    Plant J; 2008 Sep; 55(6):940-53. PubMed ID: 18532978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-regulation of B-Myb expression by E2F1 and EGF receptor.
    Hanada N; Lo HW; Day CP; Pan Y; Nakajima Y; Hung MC
    Mol Carcinog; 2006 Jan; 45(1):10-7. PubMed ID: 16299810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
    Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
    J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis.
    Musa J; Aynaud MM; Mirabeau O; Delattre O; Grünewald TG
    Cell Death Dis; 2017 Jun; 8(6):e2895. PubMed ID: 28640249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells.
    Davis JN; McCabe MT; Hayward SW; Park JM; Day ML
    Cancer Res; 2005 May; 65(9):3633-42. PubMed ID: 15867358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.